Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.
Chen HM, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, Alsina-Beauchamp D, Duty JA, Mungamuri SK, Zhang B, Moran T, Flavell R, Aaronson S, Hu HM, Arase H, Ramanathan S, Flores R, Pan PY, Chen SH.
Chen HM, et al. Among authors: aaronson s.
J Clin Invest. 2018 Dec 3;128(12):5647-5662. doi: 10.1172/JCI97570. Epub 2018 Oct 22.
J Clin Invest. 2018.
PMID: 30352428
Free PMC article.